Onyx Pharmaceuticals Announces December 2010 Investor Events

American Society of Hematology (ASH) Briefing and Analyst Briefing

Emeryville, CA. — Nov. 18, 2010

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that the company will host two investor events in December:

ASH Briefing
December 7, 2021 – 10:00 a.m. ET
Investigators will discuss data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. The teleconference will begin at 10:00 a.m. ET on December 7, 2010. The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-585-4405 and using the passcode 28465587. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 28465587# later in the day. The replay will be available on the Onyx website through December 21, 2010.

Analyst Briefing on Development Program
December 14, 2021 – 8:30 a.m. ET
Onyx management will host an overview of its development program on December 14, 2021 at 8:30 a.m. ET. The program will feature presentations on multiple tumor types by external clinical investigators and members of management. Subsequent to the prepared remarks, the company will conduct a Q&A session with panelists and members of the management team.  A replay will be available until December 28, 2010.

The live webcast will be available at:

http://investor.shareholder.com/media/eventdetail.cfm?eventid=88245&CompanyID=ABEA-3ZQWBY&e=1&mediaKey=4A4EC5744A1EE0C2C6BAA4371A3F2CE4

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company’s website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals

Return to 2010 Press Releases